The earlier research also showed that giving older mice blood transfusions from younger mice can restore some biomarkers to youthful levels, sort of like a rejuvenation process. Speaking on a podcast earlier this year, Church said: “We have already done a bunch of trials in mice and we are doing some in dogs, and then we’ll move on to humans.”

He even offered himself up as the human test subject if the technology is proven safe. He went on to say his goal is to “have the body and mind of a 22-year-old but the experience of a 130-year-old.”

Rejuvenate Bio is notoriously private but documents obtained by MIT Technology Review showed the company has tested its gene therapy on four beagles with Tufts Veterinary School in Boston. Church says that even if the gene therapy does “reverse-age” humans, it could still be profitable for dogs.

“Dogs are a market in and of themselves,” Church said. “It’s not just a big organism close to humans. It’s something people will pay for, and the FDA process is much faster. We’ll do dog trials, and that’ll be a product, and that’ll pay for scaling up in human trials.”

This isn’t all talk, either. Rejuvenate Bio has received a grant from the U.S. Special Operations Command to look into “enhancing” military dogs. So how exactly does this work? Take a look below…

Watch More On CRISPR/Cas9:

SHARE this post on Facebook…